MDimune Inc. enters into a Research Collaboration Agreement with Australian National University to collaborate on the development of therapeutics for age-related macular degeneration

October xxth, 2022 – MDimune Inc., a Korean biotech company developing BioDroneTM platform technology based on cell-derived vesicles (CDVs), announced a research collaboration agreement with the Clear Vision Research Lab (CVR Lab) at the Australian National University (ANU), experts in retinal degenerations.

MDimune and researchers at the CVR, led by Associate Professor Riccardo Natoli, conducted preclinical studies earlier this year using CDVs derived from stem cells, produce by MDimune. After observing promising results that demonstrated the therapeutic efficacy of CDVs in a model which recapitulates aspects of age-related macular degeneration (AMD), MDimune and ANUs CVR Lab decided to expand their collaboration.   

MDimune develops BioDrone™ platform technology which utilizes CDVs obtained using its proprietary extrusion technology as a next-generation drug delivery system. This novel class of drug carriers is highly versatile and can be generated from various types of human cells at high production yields.

The CVR Lab at ANU is a research group with expertise in retinal diseases. The research team is focused on developing novel innovative diagnostic and therapeutic strategies for neurodegenerative diseases using microRNAs and extracellular vesicles. CVR labs primary focus is finding treatments for age-related macular degeneration (AMD), the debilitating disease that causes vision loss in ~200 million people worldwide.  The CVR Lab has collaborated with various companies, such as Annexon Biosciences (US), Oxurion (Belgium), and Beta Therapeutic (Australia) to develop AMD therapeutics.

Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune said, “we are thrilled to launch this collaboration to develop AMD therapeutics with the world-class research group at ANU. It will be a great opportunity for us to confirm the anti-inflammatory and regenerative capacity of stem cell-derived CDVs as therapeutics. Also, through the collaboration with ANU, we anticipate that we can facilitate the commercialization of the BioDroneTM platform with global pharmaceutical companies.”  

Riccardo Natoli, Ph.D., Head of Clear Vision Research and Associate Professor at the ANU , also added, “We are excited at the possibility of the MDimune developed BioDroneTM platform technology for use as a therapeutic and drug delivery for the eye. This important work with MDimune will hopefully one day provide members of our global community affected by currently untreatable retinal diseases, such as dry AMD, sight saving treatment option’.

MDimune and ANU agreed to make a joint effort to license the AMD therapeutics developed through     collaboration.    


MDimune, Inc.

BioDrone Technology video:

Contact: Ms. Ji Sun Lee, Manager, Communication /+82 70-7826-2623/ +82 10-9008-5113/

Back to news